tbuckley/cabot-search huggingface dataset:
Association of a novel point mutation in MSH2 gene with familial multiple primary cancers
Authors: Hai Hu, Hong Li, Feng Jiao, Ting Han, Meng Zhuo, Jiujie Cui, Yixue Li, Liwei Wang
Journal: Journal of Hematology & Oncology (2017)

Multiple primary cancers (MPC) have been identified as two or more cancers without any subordinate relationship that occur either simultaneously or metachronously in the same or different organs of an individual. Lynch syndrome is an autosomal dominant genetic disorder that increases the risk of many types of cancers. Lynch syndrome patients who suffer more than two cancers can also be considered as MPC; patients of this kind provide unique resources to learn how genetic mutation causes MPC in different tissues. We performed a whole genome sequencing on blood cells and two tumor samples of a Lynch syndrome patient who was diagnosed with five primary cancers. The mutational landscape of the tumors, including somatic point mutations and copy number alternations, was characterized. We also compared Lynch syndrome with sporadic cancers and proposed a model to illustrate the mutational process by which Lynch syndrome progresses to MPC. We revealed a novel pathologic mutation on the MSH2 gene (G504 splicing) that associates with Lynch syndrome. Systematical comparison of the mutation landscape revealed that multiple cancers in the proband were evolutionarily independent. Integrative analysis showed that truncating mutations of DNA mismatch repair (MMR) genes were significantly enriched in the patient. A mutation progress model that included germline mutations of MMR genes, double hits of MMR system, mutations in tissue-specific driver genes, and rapid accumulation of additional passenger mutations was proposed to illustrate how MPC occurs in Lynch syndrome patients. Our findings demonstrate that both germline and somatic alterations are driving forces of carcinogenesis, which may resolve the carcinogenic theory of Lynch syndrome.
Translating the role of osteogenic-angiogenic coupling in bone formation: Highly efficient chitosan-pDNA activated scaffolds can accelerate bone regeneration in critical-sized bone defects
Authors: Rosanne M. Raftery, Irene Mencía Castaño, Gang Chen, Brenton Cavanagh, Brian Quinn, Caroline M. Curtin, Sally Ann Cryan, Fergal J. O'Brien
Journal: Biomaterials (2017)
放射線曝露された局所腫瘍における選択的に活性化するアルブミン結合カスパーゼ開裂可能なプロドラッグ【Powered by NICT】
Authors: Chung Seung Woo, Choi Jeong uk, Lee Beom Seok, Byun Julia, Jeon Ok-Cheol, Kim Seong Who, Kim In-San, Kim Sang Yoon, Byun Youngro
Journal: Biomaterials (2016)
Incidencia elevada de la tos ferina en los Países Bajos desde la epidemia de 1996
Authors: S E Neppelenbroek, H de Melker, J. F.P Schellekens, M A E Conyn-Van Spaendonck
Journal: Eurosurveillance (1999)

La incidencia de la tos ferina en los Paises Bajos, segun las notificaciones de casos, aumento repentinamente en 1996 hasta alcanzar 27,2 casos por 100.000 habitantes, en relacion con el promedio de 2,3/100.000 registrado de 1989 a 1995. Los aumentos anteriores observados en 1989-1990 y 1994 reflejaron los patrones habituales en otros paises con aparicion de ciclos epidemicos cada tres a cinco anos, de modo que el brote de 1996 fue algo imprevisto. No pudo explicarse ni por cambios en la calidad de la vacuna, ni por una interferencia ocasionada por la introduccion, en 1993, de la vacunacion contra Haemophilus influenzae tipo b, ni por una disminucion en la cobertura de vacunacion (96% a la edad de 12 meses) (1,2,3).
Impact of sarcopenia on dose limiting toxicities in metastatic colorectal cancer patients (mCRC pts) receiving palliative systemic treatment
Authors: S. Kurk, P. Peeters, R. Stellato, B. Dorresteijn, M. Jourdan, G.-J. Creemers, F. Erdkamp, F. de Jongh, P. Kint, B. Poppema, S. Radema, L. Simkens, B. Tanis, M. Tjin-A-Ton, A. Van der Velden, C.J.A. Punt, M. Koopman, A. May
Journal: Annals of Oncology (2017)
Second interims analysis of the ARA Plus study: Breast Cancer (BC) adjuvant chemotherapy (CT) with and without darbepoetin- alpha, analysis of serious adverse events
Authors: K. Ziegler, M. Warm, C. Oberhoff, T. Reimer, S. Mohrmann, C. Schumacher, O. Gluz, U. Nitz, I. Zuna, F. Werner
Journal: Journal of Clinical Oncology (2007)

564 Background: TAC is one of the most effective regimens. It‘s associated with higher frequency of anemia and chemotherapy-induced neutropenia (CIN). The erythropoiesis stimulating factor (ESF) support of chemotherapy, its complications and survival effect remain unclear. Erythropoetins do prevent chemotherapy-associated anemia (CAA) and subsequent fatigue syndrome but their potential influence on survival is still unclear. One aim of this analysis is to investigate the correlation between CT, growth factor support and toxicity (SAE‘s). Methods: This ARA Plus phase III trial compare chemotherapy ±ARA in breast cancer patients &gt;18 years old, with positive lymph nodes and with M0 disease. Pts get six cycles of of 5-fluoro-uracile 500mg/m 2 , epirubicine 100mg/m 2 and cyclophosphamide 500mg/m 2 , (FEC, Bonneterre), 3-weekly or six cycles of docetaxcel 75mg/m 2 , adriamycin 50mg/m 2 and cyclophosphamide 500mg/m 2 , (TAC, BCIRG) and are randomized to ARA 500μg q3w if Hb&lt;13 g/dl or standard support care. Here arte the results. of SAE‘S. Results: A total of 756 pts (373 + ARA/383 -ARA) from 53 sites were enrolled since January 2004, there are 1234 pts. planned up to January 2008. 185 serious adverse events (SAE) are reported. Of these 185 SAE’s 100 (54%) had an ARA-therapy. Most frequent SAE’s were: leucopenia, febrile neutropenia, thrombosis and infections. In 9 (31%) out of the 29 febrile neuropenia SAE’s, ARA was given. 30 thromboses were reported (23+ARA/7-ARA s.) but only 10 at the verty time ARA was given. In 31 severe infections 16 (51,6%; n.s.) were reported in patients receiving ARA Therapy. From 43 patients with intestinal SAE‘s like Diarrhea/Mucositis/Nausea to 30 pts. (69,8 %) ARA eas given. Conclusions: The combination of CT and ARA is safe concerning febrile neutropenia and furthermore appears to be protective factor of this SAE when combined with TAC. There seem to be more SAE‘s concerning thrombosis and intestinal difficulties.These results allow to hypothesize that ARA therapy is associated with higher toxicity concerning thrombosis which could make the use of heparin necessary but on the other side it shows significant reduced neutropenia. No significant financial relationships to disclose.
<i>TCF7L2</i> Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes
Authors: Maria J. Redondo, Susan Geyer, Andrea K. Steck, Jay Sosenko, Mark Anderson, Peter Antinozzi, Aaron Michels, John Wentworth, Ping Xu, Alberto Pugliese
Journal: Diabetes Care (2017)

OBJECTIVE The phenotypic diversity of type 1 diabetes suggests heterogeneous etiopathogenesis. We investigated the relationship of type 2 diabetes–associated transcription factor 7 like 2 (TCF7L2) single nucleotide polymorphisms (SNPs) with immunologic and metabolic characteristics at type 1 diabetes diagnosis. RESEARCH DESIGN AND METHODS We studied TrialNet participants with newly diagnosed autoimmune type 1 diabetes with available TCF7L2 rs4506565 and rs7901695 SNP data (n = 810; median age 13.6 years; range 3.3–58.6). We modeled the influence of carrying a TCF7L2 variant (i.e., having 1 or 2 minor alleles) on the number of islet autoantibodies and oral glucose tolerance test (OGTT)–stimulated C-peptide and glucose measures at diabetes diagnosis. All analyses were adjusted for known confounders. RESULTS The rs4506565 variant was a significant independent factor of expressing a single autoantibody, instead of multiple autoantibodies, at diagnosis (odds ratio [OR] 1.66 [95% CI 1.07, 2.57], P = 0.024). Interaction analysis demonstrated that this association was only significant in participants ≥12 years old (n = 504; OR 2.12 [1.29, 3.47], P = 0.003) but not younger ones (n = 306, P = 0.73). The rs4506565 variant was independently associated with higher C-peptide area under the curve (AUC) (P = 0.008) and lower mean glucose AUC (P = 0.0127). The results were similar for the rs7901695 SNP. CONCLUSIONS In this cohort of individuals with new-onset type 1 diabetes, type 2 diabetes–linked TCF7L2 variants were associated with single autoantibody (among those ≥12 years old), higher C-peptide AUC, and lower glucose AUC levels during an OGTT. Thus, carriers of the TCF7L2 variant had a milder immunologic and metabolic phenotype at type 1 diabetes diagnosis, which could be partly driven by type 2 diabetes–like pathogenic mechanisms.
Alternating Horner Syndrome With <i>Vegetative Alterna</i> and Spastic Quadraparesis After Bacterial Meningitis
Authors: Adrian Budhram, Mary Feng, Rookaya Mather, Donald H. Lee, Dwight E. Moulin
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Abemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2
Authors: P.A. Kaufman, H. Iwata, P. Nikolinakos, J.T. Beck, H. Koh, J.L. Gonzalez-Trujillo, Y. Lin, S. Barriga, D. Headley, N. Bourayou, A. Llombart Cussac, G.W. Sledge
Journal: Annals of Oncology (2017)
Dysmorphophobia and the Wolf Man
Authors: Neelam A. Vashi, Mayra B. C. Maymone
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Nationwide external quality assessment (EQA) of EGFR testing in circulating tumor DNA: The French experience
Authors: M. Denis, A. Vallée, S. Charpentier, I. Nanni-Métellus, L. Lacroix, C. Jovelet, M. Francilette, D. Fetique, J-P. Bellocq, E. Rouleau
Journal: Annals of Oncology (2017)
Optimizing GME by Measuring Its Outcomes
Authors: Debra F. Weinstein
Journal: New England Journal of Medicine (2017)

Interview with Dr. Debra Weinstein on the need for consistent metrics to assess GME programs and their graduates. (10:04)Download Assessment of the impact of individual residency graduates, the performance of graduate medical education programs, and the collective contribution of our GME “system” would help inform policy decisions and facilitate efforts to cultivate evidence-based GME.
IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)
Authors: T. Powles, D.F. McDermott, B. Rini, R.J. Motzer, M.B. Atkins, L. Fong, R.W. Joseph, S.K. Pal, A. Ravaud, S. Bracarda, C. Suarez Rodriguez, M. Maio, M. Gore, V. Grünwald, M. Staehler, J. Qiu, A. Thobhani, M. Huseni, C. Schiff, B. Escudier
Journal: Annals of Oncology (2017)
Recurrence of malignant peritoneal mesothelioma: Novel insights based on standardized second look procedures.
Authors: Danielle Heller, Michael D. Kluger, Allison Greene, Joshua Leinwand, Gleneara Elizabeth Bates, John A. Chabot, Robert N. Taub
Journal: Journal of Clinical Oncology (2015)

e15204 Background: Malignant peritoneal mesothelioma (MPM) is best treated by cytoreduction and intraperitoneal chemotherapy (CIC). Although this approach dramatically improves overall survival, disease recurrence has not been studied. Methods: 125 patients underwent a two-stage CIC protocol from 1995-2014. Based on gross and histological data from the second operative cytoreduction, disease status was known at the conclusion of treatment. Recurrence-free survival was calculated using Kaplan Meier survival curves, and Cox regression identified significant prognosticators. Results: 51% of patients were male, mean age 53±14 years. 11 (9%) had sarcomatoid or biphasic histology and 24 (19%) also had thoracic mesothelioma. At completion of the second operation, 23% had no microscopic or gross disease, 19% had microscopic disease, and 47% underwent a complete cytoreduction; these subsets were considered disease-free. The remaining 11% could not be optimally debulked. 42% of the 111 disease-free patients recurred based on tri-monthly surveillance imaging. Median time to recurrence was 80 months (95%CI: 60-121). Median recurrence-free survival insignificantly varied by subgroup (p = 0.22): 131 months (95%CI: 61-NR) for those without microscopic or gross disease, 74 months (95%CI: 29-144) for microscopic disease, and 69 months (95%CI: 56-88) for complete cytoreduction. Absence of microscopic disease was not protective when compared to presence of microscopic disease or complete cytoreduction of gross disease [HR: 1.2 (95%CI: 0.5-2.9) and HR:1.4 (95%CI: 0.6-3.2), respectively]. Only male gender and omission of heated intraperitoneal chemotherapy were predictors of recurrence (HR: 2.61; 95%CI: 1.4-4.9 and HR:2.4; 95%CI: 1.3-4.6, respectively). 1- and 8-year recurrence-free survival rates were 95% (95%CI: 88-98) and 39% (95%CI: 26-51). Median survival for all patients was 69 months (95%CI: 52-122) Conclusions: After optimal CIC for MPM, recurrence occurs in 42% at a median of 80 postoperative months. Regardless of whether microscopic disease is present after CIC, recurrences appear slowly on imaging and are amenable to treatment, though the benefit of retreatment is not yet established.
Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: M. Eisenberger, A-C. Hardy-Bessard, C.S. Kim, L. Géczi, D. Ford, L. Mourey, J. Carles, P. Parente, A. Font, G. Kacsó, G. Barnes, H. Wang, W. Zhang, A. Ozatilgan, J. de Bono
Journal: Annals of Oncology (2017)
GW28-e1232 Predictors and Outcomes of Cardiac Resynchronization Therapy Extended to the Second Generator
Authors: Xuping Li, Dachun Yang, Fred Kusumoto Fred, Win-Guang Shen, Siva Mulpuru, Zhenghua Zhou, Gang Wu, Mei Yang, Jin-Qu Liu, Zhuo Li, Paul A. Friedman, Yong-Mei Cha
Journal: Journal of the American College of Cardiology (2017)
Vigilância da malária em Itália: análise dos dados de 1986-1996 e dados provisórios de 1997
Authors: G Sabatinelli, G Majori
Journal: Eurosurveillance (1998)

Durante seculos, a malaria foi endemica em regioes da Italia que tinham grandes pântanos. Trabalhos de hidraulica reduziram grandemente a transmissao da malaria, mas em algumas regioes alagadicas, com menos de 800 metros abaixo do nivel do mar, a doenca ainda era muito comum quando a segunda guerra mundial comecou e as perturbacoes por ela provocadas causaram um marcado aumento da transmissao da malaria.
Abstract 18552: Ulk1-Dependent Mitochondrial Autophagy Protects the Heart Against Pressure Overload-Induced Heart Failure
Authors: Akihiro Shirakabe, Yoshiyuki Ikeda, Toshiro Saito, Peiyong Zai, Junichi Sadoshima
Journal: Circulation (2016)

Mitochondrial autophagy (MA) degrades damaged mitochondria during heart failure. MA is activated after transverse aortic constriction (TAC) with a time course distinct from general autophagy, suggesting that MA is activated by a mechanism distinct from conventional autophagy. In order to elucidate the mechanism of MA during pressure overload (PO), loss-of-function mouse models of autophagy, including  beclin1  systemic heterozygous knockout (KO) ( beclin1 -hetKO),  atg7  cardiac-specific KO ( atg7 -CKO), and  ulk1 cardiac-specific KO ( ulk1 -CKO) mice, and respective control mice were subjected to TAC for 7-28 days. In electron microscopic analyses, MA was observed in control and  atg7 -CKO mice (0.32±0.04%, 0.93±0.57%; MA number/mitochondria number) but rarely in  beclin 1 -hetKO (0.02±0.02%) and  ulk1 -CKO mice (0.01±0.02%) at 7 days of TAC. Cox I/GAPDH and mitochondrial DNA content, indexes of mitochondrial content, were significantly decreased in control and  atg7 -CKO but were increased in  beclin 1 -hetKO mice and  ulk1 -CKO mouse hearts at 7 days of TAC. These results suggest that both Beclin1 and Ulk1 mediate MA in response to PO. As expected, LC3-II, an index of conventional autophagy, was significantly decreased and more p62 was accumulated in control,  atg7 -CKO, and  beclin 1 -hetKO mice but not in  ulk1 -CKO mice at 14 days of TAC, suggesting that PO-induced activation of conventional autophagy is Beclin 1- and Atg7-dependent. Left ventricular ejection fraction (EF) was decreased at 7 days (60.4±3.5, 75.6±1.7, p beclin 1 -hetKO compared to control mice. In  atg7 -CKO mice, although EF was decreased at 7 days (54.0±2.3%, p ulk1 -CKO mice. In summary, both Beclin1 and Atg7 mediate conventional autophagy, whereas Beclin1 and Ulk1 mediate MA in response to PO. Beclin1/Atg7-dependent general autophagy protects the heart during the acute phase, whereas Beclin1/Ulk1-mediated MA protects the heart during the later phase of PO-induced cardiac hypertrophy.
TPL2 (Therapeutic Targeting Tumor Progression Locus-2)/ATF4 (Activating Transcription Factor-4)/SDF1α (Chemokine Stromal Cell-Derived Factor-α) Axis Suppresses Diabetic Retinopathy
Authors: De-Wei Lai, Keng-Hung Lin, Wayne Huey-Herng Sheu, Maw-Rong Lee, Chung-Yu Chen, Wen-Jane Lee, Yi-Wen Hung, Chin-Chang Shen, Tsung-Ju Chung, Shing-Hwa Liu, Meei-Ling Sheu
Journal: Circulation Research (2017)

Diabetic retinopathy is characterized by vasopermeability, vascular leakage, inflammation, blood-retinal barrier breakdown, capillary degeneration, and neovascularization. However, the mechanisms underlying the association between diabetes mellitus and progression retinopathy remain unclear.TPL2 (tumor progression locus 2), a serine-threonine protein kinase, exerts a pathological effect on vascular angiogenesis. This study investigated the role of Nε-(carboxymethyl)lysine, a major advanced glycation end products, and the involved TPL2-related molecular signals in diabetic retinopathy using models of in vitro and in vivo and human samples.Serum Nε-(carboxymethyl)lysine levels and TPL2 kinase activity were significantly increased in clinical patients and experimental animals with diabetic retinopathy. Intravitreal administration of pharmacological blocker or neutralizing antibody inhibited TPL2 and effectively suppressed the pathological characteristics of retinopathy in streptozotocin-induced diabetic animal models. Intravitreal VEGF (vascular endothelial growth factor) neutralization also suppressed the diabetic retinopathy in diabetic animal models. Mechanistic studies in primary human umbilical vein endothelial cells and primary retinal microvascular endothelial cells from streptozotocin-diabetic rats, db/db mice, and samples from patients with diabetic retinopathy revealed a positive parallel correlation between Nε-(carboxymethyl)lysine and the TPL2/chemokine SDF1α (stromal cell-derived factor-α) axis that is dependent on endoplasmic reticulum stress-related molecules, especially ATF4 (activating transcription factor-4).This study demonstrates that inhibiting the Nε-(carboxymethyl)lysine-induced TPL2/ATF4/SDF1α axis can effectively prevent diabetes mellitus-mediated retinal microvascular dysfunction. This signaling axis may include the therapeutic potential for other diseases involving pathological neovascularization or macular edema.
A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO
Authors: E. Terpos, M.A. Dimopoulos, E. Kastritis, J.M. Schecter, J. Ukropec, E. Smith, P. Sonneveld
Journal: Annals of Oncology (2017)
GW28-e1171 The effect of Intra-coronary Bivalirudin injection during primary PCI on coronary blood flow and clinical events in patients with acute ST segment elevation myocardial infarction: A Pilot Study
Authors: Zhenyang Liang, Xuedong Zhao, Haiwei Liu, Kai Xu, Meili Liu, Xin Zhao, Shaoping Nie, Yaling Han, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Main Plenary Sessions: Summaries of Papers
Authors: J. Schofield, A. Irvine, S. Jackson, T. Padlard, S. Gunn, N. Evans
Journal: British Journal of Dermatology (2005)

The definitive version can be found at: http://onlinelibrary.wiley.com/ Copyright British Association of Dermatologists & Blackwell [Full text of this article is not available in the UHRA]
GW28-e0420 A human iPSC-based model of diabetic endotheliopathy reveals impaired autophagy that is rescued by calpain inhibition
Authors: Sang-Bing Ong, Won Hee Lee, Nur Izzah Ismail, Khairunnisa Katwadi, Xiu Yi Kwek, Kroekkiat Chinda, Sang Ging Ong
Journal: Journal of the American College of Cardiology (2017)
Total FAK protein expression is related with anti-angiogenic therapy response in colorectal cancer models
Authors: M. Cruz Ramos, A. Cebrian, M. Rodríguez-Remírez, L. Del Puerto-Nevado, G.A. Martinez-Nava, K. Martínez-Flores, L. García, J. García-Foncillas
Journal: Annals of Oncology (2017)
Becoming Literate in Health Literacy
Authors: Richard Carmona, Andrew Pleasant
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal